Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Novo Nordisk A/S (NVO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 116,067,680
  • Shares Outstanding, K 2,443,530
  • Annual Sales, $ 16,967 M
  • Annual Income, $ 5,792 M
  • 36-Month Beta 0.65
  • Price/Sales 6.84
  • Price/Cash Flow 18.50
  • Price/Book 14.77

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate 0.61
  • Number of Estimates 1
  • High Estimate 0.61
  • Low Estimate 0.61
  • Prior Year 0.62
  • Growth Rate Est. (year over year) -1.61%

Price Performance

See More
Period Period Low Period High Performance
1-Month
46.88 +1.67%
on 09/19/18
49.98 -4.64%
on 08/29/18
-1.52 (-3.09%)
since 08/21/18
3-Month
45.19 +5.47%
on 06/28/18
51.64 -7.71%
on 07/26/18
+1.26 (+2.72%)
since 06/21/18
52-Week
44.28 +7.65%
on 06/12/18
58.37 -18.35%
on 01/23/18
-1.40 (-2.85%)
since 09/21/17

Most Recent Stories

More News
Ontario becomes first province to provide public funding of TRESIBA® for adults with diabetes mellitus

TRESIBA(®) is the first insulin added to Health Canada's Register of Innovative Drugs

NVO : 47.66 (+0.34%)
Novo Nordisk - Oral semaglutide demonstrates greater reductions in HbA1c and body weight and comparable number of adverse events vs dulaglutide in Japanese people with type 2 diabetes

Bagsvaerd, Denmark, 20 September 2018 - Novo Nordisk today announced the headline results from PIONEER 10, a phase 3a trial with oral semaglutide vs once-weekly subcutaneous dulaglutide, both in combination...

NVO : 47.66 (+0.34%)
Novo Nordisk to Restructure R&D Unit & Lay Off 400 Staff

Novo Nordisk (NVO) plans to restructure and reallocate resources in its Research and Development organization and lay off 400 employees from the unit.

NVO : 47.66 (+0.34%)
LLY : 106.33 (+0.25%)
RHHBY : 30.6200 (+0.07%)
BMY : 62.25 (+0.81%)
EyePoint Pharmaceuticals Reports Fiscal 2018 Fourth Quarter & Full Year Financial Results and Highlights Recent Progress

-Substantial progress made in the Company's accelerated transformation into a commercial entity

NVO : 47.66 (+0.34%)
EYPT : 2.60 (+4.00%)
EyePoint Pharmaceuticals Elects Goran Ando, M.D. as Next Chairman of Board of Directors

EyePoint Pharmaceuticals (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that the Company's Board of Directors...

NVO : 47.66 (+0.34%)
EYPT : 2.60 (+4.00%)
Novo Nordisk's Ozempic Lowers Risk of Cardiovascular Events (revised)

Novo Nordisk (NVO) announces post hoc results from SUSTAIN 6 study demonstrating that Ozempic consistently reduces the risk of major cardiovascular (CV) events across type II diabetes population.

NVO : 47.66 (+0.34%)
MRK : 71.10 (+0.45%)
LLY : 106.33 (+0.25%)
GILD : 75.51 (+0.91%)
Ossianix and Novo Nordisk Sign Research and Option Agreement on Blood Brain Barrier Delivery Technology for Proteins in Diabetes and Other Metabolic Diseases

Ossianix, Inc. today announced a research collaboration and option agreement with Novo Nordisk to deliver therapeutic molecules in diabetes and other metabolic diseases across the Blood Brain...

NVO : 47.66 (+0.34%)
Sanofi's Blood Disorder Drug Cablivi Gets Approval in Europe

Sanofi's (SNY) Cablivi receives approval for the treatment of acquired thrombotic thrombocytopenic purpura, a rare blood clotting disorder.

NVO : 47.66 (+0.34%)
LLY : 106.33 (+0.25%)
ALNY : 94.57 (-0.67%)
SNY : 43.55 (-1.36%)
Emisphere's Proprietary Eligen Technology Supports Novo Nordisk's Oral Semaglutide

On August 20, 2018, Novo Nordisk A/S (Novo Nordisk) announced the headline results from PIONEER 5, a phase 3a trial with oral semaglutide in adults with type 2 diabetes and moderate renal impairment. A...

EMIS : 2.4000 (unch)
NVO : 47.66 (+0.34%)
Novo Nordisk's Ozempic Lowers Risk of Cardiovascular Events

Novo Nordisk (NVO) announces post hoc results from SUSTAIN 6 study demonstrating that Ozempic consistently reduces the risk of major cardiovascular (CV) events across type II diabetes population.

NVO : 47.66 (+0.34%)
MRK : 71.10 (+0.45%)
LLY : 106.33 (+0.25%)
GILD : 75.51 (+0.91%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

See More Share

Trade NVO with:

Business Summary

Novo Nordisk is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Furthermore the company is the world's largest producer of industrial enzyme products. The company believes that everyone must care for the environment and our natural...

See More

Key Turning Points

2nd Resistance Point 48.10
1st Resistance Point 47.88
Last Price 47.66
1st Support Level 47.41
2nd Support Level 47.16

See More

52-Week High 58.37
Fibonacci 61.8% 52.99
Fibonacci 50% 51.32
Fibonacci 38.2% 49.66
Last Price 47.66
52-Week Low 44.28

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar